glp-1 agonist diarrhea Your guide to side effects GLP-1 Diarrhea: Causes, Management &

Most common side effects were gastrointestinal, with 24.5% of participants in the phase 2 obesity trial discontinuing efinopegdutide 10 mg due to AE however when the same dose was used with gradual escalation at the MASLD trial (starting dose 2.4 mg for 4 weeks, then 5 mg for 4 weeks and then 10 mg), only 5.6% of participants discontinued the medication due to AE

(Wilding et al., NEJM 2021) Oral semaglutide: Rybelsus approved for T2D in 2019

Despite being a non-communicable disorder, diabetes is considered one of the five biggest morbidities worldwide (1)

GLP-1 receptor expression in human tumors and human normal tissues: potential for in vivo targeting

Bupropion may increase the risk of suicidal thoughts or actions in some children, teenagers, and young adults within the first few months of treatment